Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Quince Therapeutics, now IRulya Therapeutics, has successfully closed a $115 million private placement in May 2026 to support its development of LAM-001.
Amount Raised
$115 Million
Round Type
Post-IPO Equity
Description
Quince Therapeutics has rebranded to IRulya Therapeutics while advancing its investigational drug LAM-001 for pulmonary diseases. The company secured $115 million in a private placement in May 2026 to aid clinical operations through 2028. New leadership aims to transform the treatment paradigm in its focused area. Stock will start trading under the ticker 'IRLA' on October 12, 2026.
Fundz sees it the moment Quince Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Quince Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.